MK3207 (CAS: 957116-20-0), also known as MK-3207 hydrochloride HCL, is a selective and potent agonist of the sphingosine-1-phosphate receptor 1 (S1P1). It is an investigational drug that is currently being studied for its potential therapeutic use in various diseases.
Chemical name: MK3207 has the chemical name of 2-butyl-5-chloro-N-(2-(4-((2R)-2-hydroxy-3-(propan-2-ylamino)propoxy)phenyl)ethyl)pyridine-3-carboxamide hydrochloride.
Molecular formula: The molecular formula of MK3207 is C26H34ClN3O3·HCl.
Formula weight: The formula weight of MK3207 is 530.44 g/mol.
CAS No: MK3207 has the CAS number of 957116-20-0.
Top ten keywords from Google and Synonyms:
Synonyms: MK3207 can also be referred to as (2-butyl-5-chloro-N-(2-(4-((2R)-2-hydroxy-3-(isopropylamino)propoxy)phenyl)ethyl)pyridine-3-carboxamide hydrochloride or UNII-TZP7V394DS.
Health benefits of this product: MK3207 has shown potential therapeutic benefits in various diseases. As an S1P1 agonist, it works by activating the S1P1 receptor, which plays a critical role in immune cell trafficking. By regulating immune cell movement, MK3207 may provide a new treatment option for autoimmune diseases such as multiple sclerosis, psoriasis, and inflammatory bowel disease.
Potential effects: MK3207 has the potential to significantly improve the treatment of various autoimmune diseases. Its high potency and selectivity make it a promising candidate for new therapies. In addition, because it targets the S1P1 receptor, it may provide a new treatment option for diseases that are resistant to other therapies.
Product mechanism: MK3207 works by selectively activating the S1P1 receptor, which regulates immune cell movement. By activating this receptor, MK3207 prevents immune cells from exiting lymphoid organs and entering the inflamed tissues. This leads to a reduction in inflammation and tissue damage associated with autoimmune diseases.
Safety: MK3207 has been shown to be generally safe and well-tolerated in clinical trials. However, more research is needed to determine its safety profile in humans.
Side effects: Currently, there is limited data available on the side effects of MK3207 in humans. However, some potential side effects may include headache, fatigue, and upper respiratory tract infections.
Dosing information: The appropriate dose of MK3207 depends on several factors including age, weight, and the specific condition being treated. It is important to follow the dosing instructions provided by the healthcare provider and to take the medication at the same time each day to maintain consistent levels in the bloodstream.
Conclusion: MK3207 is a promising new S1P1 agonist being developed for the treatment of autoimmune diseases. It has been shown to be highly effective in selectively activating the S1P1 receptor, thereby preventing immune cells from entering inflamed tissues. While there is limited data available on its safety profile in humans, MK3207 may provide a new treatment option for diseases that are resistant to other therapies. As more data becomes available from ongoing clinical trials, we will continue to learn more about the safety and efficacy of MK3207 as a potential therapeutic agent.
